News Agency
Men's Weekly

Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting

  • Written by PR Newswire

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study

SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. ("Yingli Pharma"), a biopharmaceutical company focused on developing oral therapies for cancer and...

Read more: Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or...

Improving Internal Feedback Loops Through CMS-Based Commenting and Versioning

Collaboration is essential for successful digital content creation. Unfortunately, in many companies, the feedback mechanism between marketing, design, product and development functions is less than cohesive. For example, feedback is left in email chains, instant chat messages, or within locked... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion